Hem › Triplenegativ bröstcancer › Pennsylvania › Philadelphia
Kliniska studier för Triplenegativ bröstcancer i Philadelphia, PA
13 studier för Triplenegativ bröstcancer söker deltagare vid platser i och runt Philadelphia (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RekryterarFas 1/2
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
RekryterarFas 1
- Sidney Kimmell Cancer Center - Jefferson Health, Philadelphia
Study of AVZO-021 in Patients With Advanced Solid Tumors
RekryterarFas 1/2
- Avenzo Therapeutics Recruiting Site, Philadelphia
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
RekryterarFas 3
- Sidney Kimmel Cancer Center at Jefferson ( Site 0049), Philadelphia
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
RekryterarFas 2
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
RekryterarFas 3
- University of Pennsylvania Abramson Cancer Center, Philadelphia
- Lankenau Medical Center, Wynnewood · 7 mi bort
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
RekryterarFas 1
- Normunity Investigational Site, Philadelphia
- Normunity Investigational Site, Philadelphia
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
RekryterarFas 2/3
- Abramson Cancer Center of The University of Pennsylvania, Philadelphia
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RekryterarFas 2
- University of Pennsylvania (U Penn), Philadelphia
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
RekryterarFas 2
- University of Pennsylvania-Abramson Cancer Center, Philadelphia
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RekryterarFas 2
- University of Pennsylvania-Abramson Cancer Center, Philadelphia
Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer
Rekryterar
- Thomas Jefferson University Hospital, Philadelphia
Role of the Immune Environment in Response to Therapy in Breast Cancer
RekryterarObservationsstudie
- Abramson Cancer Center, Philadelphia
Triplenegativ bröstcancer-studier i andra städer
- Houston, TX42 studier
- New York City, NY31 studier
- Nashville, TN28 studier
- Los Angeles, CA27 studier
- Boston, MA26 studier
- San Antonio, TX23 studier
- St. Louis, MO21 studier
- Arlington, VA20 studier
- Atlanta, GA20 studier
- Dallas, TX18 studier
- Chicago, IL16 studier
- Columbus, OH16 studier
Andra studier i Philadelphia
- Cancer (alla typer)59 studier
- Bröstcancer56 studier
- Icke-småcellig lungcancer51 studier
- Metastaserande cancer46 studier
- Prostatacancer44 studier
- Kolorektal cancer44 studier
- Äggstockscancer44 studier
- Lungcancer36 studier
- Akut myeloid leukemi34 studier
- Hjärtsvikt31 studier
- Endometriecancer28 studier
- Depression26 studier
Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.